Senseonics Holdings, Inc. (SENS)
SENSNASDAQ-GSMedical/Dental Instruments
$11.62
+1.82 (+18.53%) today
At the close, Nov 9, 4:00 PM ET. Pre-market $11.65 +18.88%
- Market cap
- $615.98m
- P/E
- –
- EPS, last 4 quarters
- $-2.23
- Dividend yield
- –
- Day range
- –
- 52-week range
- $4.79 to $10.64
- Average volume
- 670.6k
- Previous close
- $9.80
Analysts
6 coveringHold3 buy, 3 hold, 0 sell
Targets a year out average $12.00, +3.3% from here
Earnings
next estimate $-0.4900Next report
Sep 2025
-30.3%
Dec 2025
-7.0%
Mar 2026
-9.2%
Jun 2026
-14.6%
estimate reported, and the surprise
Financials
| Quarter | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | $8.10m | $14.26m | $11.71m | $14.48m |
| Gross profit | $3.47m | $7.67m | $6.94m | $8.56m |
| Operating income | -$19.60m | -$20.93m | -$31.85m | -$35.99m |
| Net income | -$19.53m | -$20.82m | -$32.33m | -$36.70m |
Last four quarters: revenue $48.55m, margin -225.3%, free cash flow -$96.83m
News
8 latest- Senseonics Shares Rise 12% As Q3 Revenue Jumps 140%; FY26 Outlook Raised RTTNews · 1 hour ago
- Senseonics Holdings (SENS) Reports Q3 Loss, Beats Revenue EstimatesZacks · 14 hours ago
- Evolent Health (EVH) Matches Q3 Earnings EstimatesZacks · 5 days ago
- Barclays Initiates Coverage of Senseonics Holdings at Equal-WeightFintel · Oct 7, 2026
- Beta Bionics Stock Down Despite iLet-Eversense 365 Integration DealZacks · Sep 29, 2026
- Beta Bionics: FDA Clearance Of Mint Sets Stage For 2027 Patch Pump Launch RTTNews · Sep 14, 2026
- Is DXCM Stock Worth Buying as Growth Improves but Valuation Stretches?Zacks · Aug 12, 2026
- DXCM Stock Up Nearly 35% YTD: Will the Uptrend Continue in the Rest of 2026?Zacks · Aug 12, 2026
The company
Senseonics Holdings, Inc. ('Senseonics') is a diabetes company redefining continuous glucose monitoring (CGM) with long-term implantable sensing technology. Driven by a mission to transform lives in the diabetes community, Senseonics is the maker of Eversense 365, the world's first and only one-year CGM system, and is advancing a differentiated pipeline of innovation. By commercializing Eversense 365 and pushing the boundaries of sensing technology, Senseonics is empowering better diabetes management, reducing the device burden, expanding patient choice, and shaping the future of diabetes care.
- Sector
- Health Care
- Industry
- Medical/Dental Instruments
- Exchange
- NASDAQ-GS
- Region
- North America
- Website
- senseonics.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.